CL2012001143A1 - Anticuerpo anti-fractalkina (anti-fkn); composicion farmaceutica que comprende dicho anticuerpo anti-fkn; acido nucleico; vector; celula huesped; uso del anticuerpo anti-fkn para tratar trastornos inflamatorios. - Google Patents

Anticuerpo anti-fractalkina (anti-fkn); composicion farmaceutica que comprende dicho anticuerpo anti-fkn; acido nucleico; vector; celula huesped; uso del anticuerpo anti-fkn para tratar trastornos inflamatorios.

Info

Publication number
CL2012001143A1
CL2012001143A1 CL2012001143A CL2012001143A CL2012001143A1 CL 2012001143 A1 CL2012001143 A1 CL 2012001143A1 CL 2012001143 A CL2012001143 A CL 2012001143A CL 2012001143 A CL2012001143 A CL 2012001143A CL 2012001143 A1 CL2012001143 A1 CL 2012001143A1
Authority
CL
Chile
Prior art keywords
fkn
antibody
fractalkin
vector
nucleic acid
Prior art date
Application number
CL2012001143A
Other languages
English (en)
Spanish (es)
Inventor
Miyuki Nishimura
Yoshimasa Sakamoto
Tetsu Kawano
Toshio Imai
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001143(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2012001143A1 publication Critical patent/CL2012001143A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2012001143A 2009-10-30 2012-04-30 Anticuerpo anti-fractalkina (anti-fkn); composicion farmaceutica que comprende dicho anticuerpo anti-fkn; acido nucleico; vector; celula huesped; uso del anticuerpo anti-fkn para tratar trastornos inflamatorios. CL2012001143A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30

Publications (1)

Publication Number Publication Date
CL2012001143A1 true CL2012001143A1 (es) 2012-10-05

Family

ID=43922220

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2012001143A CL2012001143A1 (es) 2009-10-30 2012-04-30 Anticuerpo anti-fractalkina (anti-fkn); composicion farmaceutica que comprende dicho anticuerpo anti-fkn; acido nucleico; vector; celula huesped; uso del anticuerpo anti-fkn para tratar trastornos inflamatorios.
CL2015000114A CL2015000114A1 (es) 2009-10-30 2015-01-15 Anticuerpo anti-fractalkina (anti-fkn): composición farmacéutica que comprende dicho anticuerpo anti-fkn; ácido nucleico; vector; célula huésped; uso del anticuerpo anti-fkn para tratar colitis ulcerosa, enfermedad de crohn, o artritis reumática

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2015000114A CL2015000114A1 (es) 2009-10-30 2015-01-15 Anticuerpo anti-fractalkina (anti-fkn): composición farmacéutica que comprende dicho anticuerpo anti-fkn; ácido nucleico; vector; célula huésped; uso del anticuerpo anti-fkn para tratar colitis ulcerosa, enfermedad de crohn, o artritis reumática

Country Status (33)

Country Link
US (1) US8932592B2 (https=)
EP (1) EP2493930B1 (https=)
JP (2) JP5631991B2 (https=)
KR (2) KR102099596B1 (https=)
CN (1) CN102597003B (https=)
AR (2) AR078796A1 (https=)
AU (1) AU2010312408B2 (https=)
BR (1) BR112012010266A2 (https=)
CA (1) CA2778895C (https=)
CL (2) CL2012001143A1 (https=)
CY (1) CY1121167T1 (https=)
DK (1) DK2493930T3 (https=)
ES (1) ES2698389T3 (https=)
HR (1) HRP20181973T1 (https=)
HU (1) HUE041952T2 (https=)
IL (1) IL219470A (https=)
JO (1) JO3437B1 (https=)
LT (1) LT2493930T (https=)
MX (1) MX2012005052A (https=)
MY (1) MY158481A (https=)
NZ (1) NZ599779A (https=)
PE (1) PE20121645A1 (https=)
PH (1) PH12012500828A1 (https=)
PL (1) PL2493930T3 (https=)
PT (1) PT2493930T (https=)
RS (1) RS58142B1 (https=)
RU (1) RU2569109C2 (https=)
SI (1) SI2493930T1 (https=)
SM (1) SMT201800637T1 (https=)
TW (1) TWI414308B (https=)
UA (1) UA105073C2 (https=)
WO (1) WO2011052799A1 (https=)
ZA (1) ZA201203002B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
US20220196674A1 (en) * 2019-04-17 2022-06-23 Abdolamir Landi Treatment of autoimmune liver disease
US20220205980A1 (en) * 2019-04-23 2022-06-30 Eisai R&D Management Co., Ltd. Biomarker for rheumatoid arthritis treatment
KR20220110827A (ko) * 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 시신경척수염 스펙트럼 장애의 치료를 위한 항-c5 항체
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
WO2022092183A1 (ja) 2020-10-30 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
CN121537534B (zh) * 2026-01-22 2026-04-07 华中科技大学同济医学院附属协和医院 靶向cx3cl1的嵌合抗原受体-巨噬细胞及在gjb2突变相关遗传性耳聋治疗中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
AU691811B2 (en) * 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
CA2225852C (en) * 1995-06-30 2009-04-14 Mochida Pharmaceutical Co., Ltd. Anti-fas ligand antibody and assay method using the anti-fas ligand antibody
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
EP0876487B1 (en) 1996-01-24 2008-03-12 Schering Corporation Mammalian cx3c chemokine genes
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
US6043086A (en) * 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
EP0966484A4 (en) 1996-05-07 2002-04-17 Millennium Pharm Inc NEUROTACTIN AND APPLICATIONS THEREOF
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
WO2000011950A1 (en) 1998-08-31 2000-03-09 Oregon Health Science University Prevention of cell migration initiation with cmv us28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2001060406A1 (en) * 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
WO2003018549A2 (en) 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
WO2005032589A1 (ja) * 2003-10-02 2005-04-14 Japan Science And Technology Agency Ｇｖｈｄの予防及び治療
CA2541533A1 (en) 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
PT2094728E (pt) * 2006-10-26 2013-05-27 Janssen Biotech Inc Métodos de adaptação de anticorpos monoclonais ao ser humano
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.

Also Published As

Publication number Publication date
WO2011052799A1 (en) 2011-05-05
DK2493930T3 (en) 2018-12-17
US20120213799A1 (en) 2012-08-23
AU2010312408B2 (en) 2015-07-09
AR078796A1 (es) 2011-12-07
EP2493930B1 (en) 2018-09-19
CL2015000114A1 (es) 2015-04-10
TW201127401A (en) 2011-08-16
PT2493930T (pt) 2018-11-29
US8932592B2 (en) 2015-01-13
CN102597003B (zh) 2016-03-23
HUE041952T2 (hu) 2019-06-28
KR20160066055A (ko) 2016-06-09
CA2778895C (en) 2018-08-07
CA2778895A1 (en) 2011-05-05
SI2493930T1 (sl) 2018-12-31
PH12012500828A1 (en) 2013-01-07
KR101627605B1 (ko) 2016-06-07
AR109533A2 (es) 2018-12-19
ZA201203002B (en) 2013-06-26
TWI414308B (zh) 2013-11-11
IL219470A (en) 2017-10-31
JP2015027304A (ja) 2015-02-12
PE20121645A1 (es) 2012-12-06
CN102597003A (zh) 2012-07-18
JP2013509158A (ja) 2013-03-14
KR20120104560A (ko) 2012-09-21
MY158481A (en) 2016-10-14
PL2493930T3 (pl) 2019-03-29
MX2012005052A (es) 2012-05-29
BR112012010266A2 (pt) 2016-12-06
RS58142B1 (sr) 2019-02-28
KR102099596B1 (ko) 2020-04-10
ES2698389T3 (es) 2019-02-04
CY1121167T1 (el) 2020-05-29
NZ599779A (en) 2014-03-28
EP2493930A4 (en) 2013-12-04
JP5631991B2 (ja) 2014-11-26
SMT201800637T1 (it) 2019-01-11
RU2012122203A (ru) 2013-12-10
HRP20181973T1 (hr) 2019-01-25
IL219470A0 (en) 2012-06-28
AU2010312408A1 (en) 2012-06-21
EP2493930A1 (en) 2012-09-05
RU2569109C2 (ru) 2015-11-20
LT2493930T (lt) 2019-01-10
JO3437B1 (ar) 2019-10-20
UA105073C2 (uk) 2014-04-10

Similar Documents

Publication Publication Date Title
CL2012001143A1 (es) Anticuerpo anti-fractalkina (anti-fkn); composicion farmaceutica que comprende dicho anticuerpo anti-fkn; acido nucleico; vector; celula huesped; uso del anticuerpo anti-fkn para tratar trastornos inflamatorios.
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
AR091098A1 (es) ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO
AR089752A1 (es) Anticuerpos anti-lrp5 y metodos de uso
CL2017000969A1 (es) Composiciones del factor viii y métodos para hacerlas y usarlas (divisional solicitud no. 2166-2014)
CL2014000958A1 (es) Polipeptidos de anticuerpos que antagonizan cd4ol; acido nucleico que codifica dicho anticuerpo; vector y célula huesped que la comprenden; composicion farmacéutica; uso de dichos polipéptidos para tratar enfermedad inmunitaria.
MX394473B (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de nrf2.
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
CR20130138A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CL2015002301A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
AR088322A1 (es) Anticuerpos anti-htra1 y metodos de uso
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
MX2016002571A (es) Regulador de ph de transduccion.
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
CL2011002611A1 (es) Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17.
BR112013023241A2 (pt) melhorias para entidades biológicas imobilizadas
CO7151485A2 (es) Anticuerpos anti-sez6 y métodos de empleo
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
UY34347A (es) Proteínas de función dual para tratar trastornos metabólicos
AR079551A1 (es) Anticuerpos anti-her3 y usos de los mismos
CL2009001066A1 (es) Compuestos derivados del acido ciclopentano carboxilico sustituido; inhibidores del receptor lpa edg2; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, metabolicas, renales, pulmonares, oncologicas, inmunologicas y alergias, entre otras.
CL2013001290A1 (es) Anticuerpo aislado, o su fragmento, que se une a beta secretasa (bace1); acido nucleico que codifica el anticuerpo; celula huesped que comprende el acido nucleico; metodo para producir un anticuerpo; inmunoconjugado que comprende el anticuerpo; formulacion farmaceutica; uso del anticuerpo para tratar enfermedad o trastorno neurológico.